Methylene blue has moved from a niche compounding-pharmacy product into a mainstream wellness conversation, discussed for everything from mitochondrial support to cognitive focus. What gets mentioned far less often is that methylene blue is pharmacologically active in ways that can interact seriously with other medications, including some of the most commonly prescribed antidepressants in the country. Before considering it, it helps to understand where those interactions come from and why a clinician needs your full medication list, not just your reason for wanting to try it.
This article is patient education, not medical advice. Only an independent licensed medical professional can determine whether methylene blue is appropriate for you, after reviewing your health history and current medications.
What methylene blue is and why interactions matter
Methylene blue is a synthetic compound with a long history in conventional medicine. It has an established, dose-specific medical use treating methemoglobinemia, a condition in which blood loses its normal capacity to carry oxygen, and it has also been used as a surgical dye and in certain laboratory and diagnostic settings. Outside of these established clinical uses, methylene blue is increasingly discussed in wellness and longevity circles, a shift our broader overview of what the science actually says about methylene blue covers in more depth; compounding pharmacies may prepare it for off-label use when a licensed physician determines it's clinically appropriate.
Compounded medications, including methylene blue prepared for off-label wellness or longevity purposes, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality. That distinction matters here specifically because the interaction risks described in this article come from methylene blue's pharmacology, not from any particular formulation or dose, which means they apply whether the product is being used for an FDA-recognized indication or an off-label wellness purpose.
The reason methylene blue interacts with other medications isn't incidental. It has measurable activity as a monoamine oxidase inhibitor (MAOI), a class of compounds that affects how the body breaks down certain neurotransmitters, including serotonin. That single property is behind most of the interactions a clinician will ask about, and it's why a complete, honest medication list matters more here than it might for a more inert supplement.
Methylene blue and serotonergic medications: the serotonin syndrome risk
The most important interaction to know about involves serotonergic medications, which includes many of the most widely prescribed antidepressants: SSRIs (such as sertraline, fluoxetine, or escitalopram), SNRIs (such as venlafaxine or duloxetine), and several other antidepressant classes. Because methylene blue inhibits monoamine oxidase, combining it with medications that already raise serotonin activity can push serotonin signaling higher than the body is designed to handle.
The FDA has specifically warned that combining methylene blue with serotonergic psychiatric medications can increase the risk of serotonin syndrome, a potentially serious reaction. Serotonin syndrome can involve agitation or restlessness, a rapid heart rate, elevated body temperature, muscle rigidity or twitching, tremor, sweating, and in more severe cases, confusion or a dangerously high fever. Mild cases can sometimes resemble a bad case of nerves; severe cases are a medical emergency.
This risk isn't limited to people who take antidepressants every day. It also matters for people who've recently stopped one, since some serotonergic medications stay active in the body for days or weeks after the last dose, and for people taking other serotonin-affecting substances they might not think to mention, including certain migraine medications (triptans), some opioid pain medications like tramadol, and over-the-counter supplements like St. John's Wort. None of these need to be disqualifying on their own, but every one of them belongs on the list you bring to a clinician considering methylene blue.
Want a clinician to review your medication list first?
Methylene blue and MAOIs: a combination to avoid
Because methylene blue itself acts as an MAOI, combining it with other monoamine oxidase inhibitors, whether prescribed for depression or, less commonly today, for Parkinson's disease, is generally avoided. Stacking two MAOIs doesn't add the risks together in a simple, predictable way; it can compound them, raising the chance of serious reactions that include not only serotonin syndrome but also a hypertensive crisis, a sudden, dangerous spike in blood pressure.
This is one reason a clinician will ask not just what you're currently taking, but what you've taken recently. Some MAOIs require a washout period, a stretch of time off the medication, before it's considered safe to start something else that affects the same pathway. Trying to shorten that window on your own, without clinician guidance, removes the safety margin the washout period is designed to provide.
The practical takeaway is straightforward even though the pharmacology is technical: if you have ever taken an MAOI, say so, including the approximate date you stopped. A clinician can't assess a timing-dependent risk from information you didn't share.
G6PD deficiency and other conditions that affect safety
Serotonergic and MAOI interactions aren't the only safety consideration. People with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited condition that affects red blood cells, are at increased risk of hemolytic anemia, a condition in which red blood cells break down faster than the body can replace them, when exposed to methylene blue. G6PD deficiency is more common in some populations than others and many people who have it don't know it unless they've been tested or had a reaction to another oxidizing medication in the past.
Kidney function is another factor clinicians typically ask about, since how a medication is cleared from the body can affect both its safety and its dosing. Pregnancy and breastfeeding are also relevant: methylene blue isn't something a clinician would recommend starting without first discussing those circumstances directly.
| Factor to disclose | Why it matters with methylene blue |
|---|---|
| SSRIs, SNRIs, or other antidepressants | Combined serotonin activity can raise the risk of serotonin syndrome |
| Any current or recent MAOI | Two MAOIs together can compound serotonin syndrome and hypertensive-crisis risk |
| Triptans, tramadol, or St. John's Wort | These also affect serotonin and can add to the same risk |
| G6PD deficiency (known or suspected) | Raises the risk of hemolytic anemia with methylene blue exposure |
| Kidney problems, pregnancy, or breastfeeding | Affects whether and how a clinician would consider methylene blue appropriate at all |
Other medications and supplements worth flagging
Interaction conversations tend to focus on prescription medications, but supplements and over-the-counter products deserve equally honest disclosure. St. John's Wort, mentioned above, is a common example: it's sold without a prescription, which leads some people to assume it's interaction-free, but it affects serotonin activity in ways that matter here. Certain cold and allergy medications, weight-management products, and other supplements marketed for mood or focus can carry similar, less-publicized serotonergic effects. This kind of thorough, no-detail-too-small disclosure matters across medication types generally, not just methylene blue, as our guide to GLP-1 medications and drug interactions explains in a different context.
The same honesty applies to anything you're taking intermittently rather than daily, including as-needed medications for migraines or pain, since a clinician needs to know about use patterns, not just standing prescriptions. If you're unsure whether something counts as relevant, the safer approach is to mention it anyway and let your clinician decide, rather than deciding on your own that it's probably fine.
It's also worth telling your clinician about any recent changes, such as starting, stopping, or adjusting the dose of an antidepressant, even if that change happened weeks ago. Because some of these medications remain active in the body well after the last dose, a change that feels like old news to you can still be directly relevant to a methylene blue safety discussion today.
What to tell your clinician before starting
Before any discussion of whether methylene blue might be appropriate for you, a licensed clinician needs a complete, current medication and supplement list, not a summary of what feels relevant. That includes prescription medications, anything you take as needed, over-the-counter products, and supplements, along with anything you've started or stopped in the recent past. Writing this list out ahead of your evaluation, rather than trying to recall it from memory in the moment, tends to produce a more accurate and useful conversation.
It's also worth mentioning any history of G6PD deficiency, kidney problems, or psychiatric medication use, even past use, along with whether you're pregnant, breastfeeding, or planning a pregnancy. None of this information is meant to discourage you from asking about methylene blue; it's what allows a clinician to actually evaluate whether it's safe for your specific situation rather than giving a generic answer that doesn't account for your history.
If a clinician determines that methylene blue isn't appropriate because of a current medication, that isn't the end of the conversation. In some cases, adjusting timing, discussing alternatives, such as other longevity-focused options like NAD+ or glutathione, or revisiting the question after a medication change is possible, but that's a decision for you and your clinician to work through together, not something to attempt on your own by skipping doses or stopping a prescribed medication without guidance. Our guide to realistic expectations for longevity protocols covers how this kind of individualized, clinician-guided decision-making applies more broadly.
The bottom line
Methylene blue's interaction profile isn't a minor footnote. Its activity as a monoamine oxidase inhibitor means it can interact seriously with common antidepressants, other MAOIs, and some supplements, primarily through the risk of serotonin syndrome, and separately, people with G6PD deficiency face an added risk of hemolytic anemia. None of this means methylene blue is automatically off the table for everyone taking these medications, but it does mean a full, honest medication history is a non-negotiable first step, not a formality. An independent licensed clinician is the right person to weigh your specific medications, history, and goals before any decision is made.
Important Safety Information
Indication. Methylene blue is a synthetic compound with an established, dose-specific medical use in conventional care, including treatment of methemoglobinemia under clinician supervision. Use for off-label wellness or longevity purposes is not an FDA-approved indication. Compounded medications, including methylene blue prepared for off-label use, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; an independent licensed physician may prescribe a compounded preparation when clinically appropriate.
Common side effects. Reported effects can include blue-green discoloration of urine or skin, gastrointestinal upset, headache, and dizziness; effects and risks are dose-dependent.
Warnings. Methylene blue acts as a monoamine oxidase inhibitor and can interact seriously with serotonergic medications, including SSRIs, SNRIs, and other MAOIs, raising the risk of serotonin syndrome and, when combined with other MAOIs, hypertensive crisis. It is generally not appropriate for people with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia. Tell your clinician about all medications and supplements, any kidney problems, and about pregnancy or breastfeeding, before considering it.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Can I take methylene blue with my antidepressant?
That depends entirely on which antidepressant and your broader health picture, and it's not a question to answer on your own. Methylene blue can interact with serotonergic medications, including many SSRIs and SNRIs, in ways that raise the risk of serotonin syndrome. A licensed clinician needs your full medication list to evaluate whether any combination is safe for you.
What is serotonin syndrome and how serious is it?
Serotonin syndrome happens when serotonin activity in the body rises too high, and it can involve agitation, a fast heart rate, elevated body temperature, muscle rigidity, and tremor. Mild cases can be uncomfortable, while severe cases are a medical emergency. It's the main reason methylene blue and serotonergic medications are discussed as a serious interaction rather than a minor caution.
Do I need to be tested for G6PD deficiency before trying methylene blue?
Whether testing is needed depends on your personal and family history and is a decision for your clinician, not something to decide alone. G6PD deficiency increases the risk of hemolytic anemia with methylene blue exposure, so mentioning any known history, or reactions to other oxidizing medications in the past, is an important part of the safety conversation.
Is it safe to stop my antidepressant on my own so I can try methylene blue?
No. Stopping or adjusting a prescribed antidepressant without clinician guidance isn't a safe way to work around an interaction, and some of these medications remain active in the body for days or weeks after the last dose. Any change to an existing prescription should be discussed with and directed by the clinician who prescribed it.
Are over-the-counter supplements like St. John's Wort relevant to this interaction?
Yes. St. John's Wort affects serotonin activity even though it's sold without a prescription, and it belongs on the same disclosure list as prescription antidepressants. The same goes for other supplements marketed for mood or focus, as well as as-needed medications like triptans or tramadol.
Is compounded methylene blue FDA-approved for wellness or longevity use?
No. Compounded medications, including methylene blue prepared for off-label wellness or longevity purposes, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality. An independent licensed physician may still prescribe a compounded preparation when clinically appropriate, based on an individual evaluation.
